The Current Status of DNA-Repair-Directed Precision Oncology Strategies in Epithelial Ovarian Cancers

Survival outcomes for patients with advanced ovarian cancer remain poor despite advances in chemotherapy and surgery. Platinum-based systemic chemotherapy can result in a response rate of up to 80%, but most patients will have recurrence and die from the disease. Recently, the DNA-repair-directed pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Hiu, Kulkarni, Sanat, Peters, Christina, Eddison, Jasper, Al-Ani, Maryam, Madhusudan, Srinivasan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10138422/
https://www.ncbi.nlm.nih.gov/pubmed/37108451
http://dx.doi.org/10.3390/ijms24087293
_version_ 1785032702979735552
author Tang, Hiu
Kulkarni, Sanat
Peters, Christina
Eddison, Jasper
Al-Ani, Maryam
Madhusudan, Srinivasan
author_facet Tang, Hiu
Kulkarni, Sanat
Peters, Christina
Eddison, Jasper
Al-Ani, Maryam
Madhusudan, Srinivasan
author_sort Tang, Hiu
collection PubMed
description Survival outcomes for patients with advanced ovarian cancer remain poor despite advances in chemotherapy and surgery. Platinum-based systemic chemotherapy can result in a response rate of up to 80%, but most patients will have recurrence and die from the disease. Recently, the DNA-repair-directed precision oncology strategy has generated hope for patients. The clinical use of poly(ADP-ribose) polymerase (PARP) inhibitors in BRCA germ-line-deficient and/or platinum-sensitive epithelial ovarian cancers has improved survival. However, the emergence of resistance is an ongoing clinical challenge. Here, we review the current clinical state of PARP inhibitors and other clinically viable targeted approaches in epithelial ovarian cancers.
format Online
Article
Text
id pubmed-10138422
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-101384222023-04-28 The Current Status of DNA-Repair-Directed Precision Oncology Strategies in Epithelial Ovarian Cancers Tang, Hiu Kulkarni, Sanat Peters, Christina Eddison, Jasper Al-Ani, Maryam Madhusudan, Srinivasan Int J Mol Sci Review Survival outcomes for patients with advanced ovarian cancer remain poor despite advances in chemotherapy and surgery. Platinum-based systemic chemotherapy can result in a response rate of up to 80%, but most patients will have recurrence and die from the disease. Recently, the DNA-repair-directed precision oncology strategy has generated hope for patients. The clinical use of poly(ADP-ribose) polymerase (PARP) inhibitors in BRCA germ-line-deficient and/or platinum-sensitive epithelial ovarian cancers has improved survival. However, the emergence of resistance is an ongoing clinical challenge. Here, we review the current clinical state of PARP inhibitors and other clinically viable targeted approaches in epithelial ovarian cancers. MDPI 2023-04-14 /pmc/articles/PMC10138422/ /pubmed/37108451 http://dx.doi.org/10.3390/ijms24087293 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Tang, Hiu
Kulkarni, Sanat
Peters, Christina
Eddison, Jasper
Al-Ani, Maryam
Madhusudan, Srinivasan
The Current Status of DNA-Repair-Directed Precision Oncology Strategies in Epithelial Ovarian Cancers
title The Current Status of DNA-Repair-Directed Precision Oncology Strategies in Epithelial Ovarian Cancers
title_full The Current Status of DNA-Repair-Directed Precision Oncology Strategies in Epithelial Ovarian Cancers
title_fullStr The Current Status of DNA-Repair-Directed Precision Oncology Strategies in Epithelial Ovarian Cancers
title_full_unstemmed The Current Status of DNA-Repair-Directed Precision Oncology Strategies in Epithelial Ovarian Cancers
title_short The Current Status of DNA-Repair-Directed Precision Oncology Strategies in Epithelial Ovarian Cancers
title_sort current status of dna-repair-directed precision oncology strategies in epithelial ovarian cancers
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10138422/
https://www.ncbi.nlm.nih.gov/pubmed/37108451
http://dx.doi.org/10.3390/ijms24087293
work_keys_str_mv AT tanghiu thecurrentstatusofdnarepairdirectedprecisiononcologystrategiesinepithelialovariancancers
AT kulkarnisanat thecurrentstatusofdnarepairdirectedprecisiononcologystrategiesinepithelialovariancancers
AT peterschristina thecurrentstatusofdnarepairdirectedprecisiononcologystrategiesinepithelialovariancancers
AT eddisonjasper thecurrentstatusofdnarepairdirectedprecisiononcologystrategiesinepithelialovariancancers
AT alanimaryam thecurrentstatusofdnarepairdirectedprecisiononcologystrategiesinepithelialovariancancers
AT madhusudansrinivasan thecurrentstatusofdnarepairdirectedprecisiononcologystrategiesinepithelialovariancancers
AT tanghiu currentstatusofdnarepairdirectedprecisiononcologystrategiesinepithelialovariancancers
AT kulkarnisanat currentstatusofdnarepairdirectedprecisiononcologystrategiesinepithelialovariancancers
AT peterschristina currentstatusofdnarepairdirectedprecisiononcologystrategiesinepithelialovariancancers
AT eddisonjasper currentstatusofdnarepairdirectedprecisiononcologystrategiesinepithelialovariancancers
AT alanimaryam currentstatusofdnarepairdirectedprecisiononcologystrategiesinepithelialovariancancers
AT madhusudansrinivasan currentstatusofdnarepairdirectedprecisiononcologystrategiesinepithelialovariancancers

Ejemplares similares